Trial Profile
An open-label, Phase 1b study of TG02 in combination with Carfilzomib assessing safety and efficacy in Carfilzomib Refractory Multiple Myeloma Patients.
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 22 Apr 2019
Price :
$35
*
At a glance
- Drugs Zotiraciclib (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions
- 21 Jan 2016 New trial record
- 08 Dec 2015 Interim results (n=24) presented at the 57th Annual Meeting and Exposition of the American Society of Hematology